Skip to main content

Table 2 Study population characteristics by hepatitis C (HCV) co-infection status

From: The impact of HCV co-infection status on healthcare-related utilization among people living with HIV in British Columbia, Canada: a retrospective cohort study

Variables

HIV mono-infected

HIV/HCV co-infected

P-value

N = 2333

N = 1622

Sex, n(%)

   

 Female

269 (37)

466 (63)

< 0.0001

 Male

2064 (64)

1156 (36)

 

Age at ART initiation (years), n(%)

   

 < 30

304 (63)

177 (37)

< 0.0001

 30–39

726 (60)

490 (40)

 

 40–49

780 (54%)

661 (46%)

 

 ≥ 50

523 (64%)

294 (36%)

 

Risk, n(%)

   

 MSM

1144 (88)

150 (12)

< 0.0001

 IDU

122 (9)

1176 (91)

 

 MSM/IDU

122 (39)

187 (61)

 

 Other

514 (88)

67 (12)

 

 Unknown

431 (91)

42 (9)

 

ART era, n(%)

   

 2000–2003

403 (51)

394 (49)

< 0.0001

 2004–2007

628 (54)

525 (46)

 

 2008–2011

1001 (63)

598 (37)

 

 2012–2013

301 (74)

105 (26)

 

Baseline CD4 cell count (cells/mm3), n(%)

   

 < 50

276 (58)

198 (42)

< 0.0001

 50–199

640 (50)

645 (50)

 

 200–349

746 (60)

492 (40)

 

 ≥ 350

671 (70)

287 (30)

 

Last CD4 cell count (cells/mm3), n(%)

   

 < 50

40 (33)

81 (67)

< 0.0001

 50–199

101 (31)

228 (69)

 

 200–349

232 (46)

277 (54)

 

 ≥ 350

1732 (67)

864 (33)

 

 Unknown

228 (57)

172 (43)

 

ART Adherence (first six months), n(%)

   

 ≥ 95%

1987 (64)

1097 (36)

< 0.0001

 80–94%

100 (48)

108 (52)

 

 40–79%

182 (41)

263 (59)

 

 < 40%

64 (29)

154 (71)

 

ART Adherence (last six months), n(%)

   

 ≥ 95%

1821 (65)

960 (35)

< 0.0001

 80–94%

122 (47)

140 (53)

 

 40–79%

224 (45)

277 (55)

 

 < 40%

166 (40)

245 (60)

 

Number of comorbidities at baseline, n(%)

   

 0

1067 (79)

290 (21)

< 0.0001

 1

745 (57)

562 (43)

 

 2

331 (46)

394 (54)

 

 ≥3

190 (34)

376 (66)

 

Number of comorbidities at the end of follow-up, n(%)

   

 0

961 (82)

215 (18)

<0.0001

 1

687 (62)

421 (38)

 

 2

333 (47)

382 (53)

 

 ≥3

352 (37)

604 (63)

 

Initial ART regimen, n(%)

   

 NNRTI

1098 (58)

797 (42)

0.2109

 bPI

1235 (60)

825 (40)

 

Total healthcare-related visits, median (Q1-Q3)

83 (43–150)

143 (68–278)

< 0.0001

Baseline viral load (log10 copies/mL), median (Q1-Q3)

4.92 (4.42–5.00)

4.87 (4.35–5.00)

0.0048

Last viral load (log10 copies/mL), median (Q1-Q3)

1.69 (1.69–1.69)

1.69 (1.69–1.98)

< 0.0001

Follow-up time (years), median (Q1-Q3)

4.95 (2.50–7.91)

5.30 (2.99–8.31)

0.0038

  1. Q1-Q3: 25th - 75th percentiles; MSM: Gay, bisexual and other men who have sex with men; PWID: people who have ever injected drugs; ART: combination antiretroviral therapy; NNRTI: non-nucleoside reverse transcriptase inhibitor; bPI: ritonavir-boosted protease inhibitor
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us